Article Text

Download PDFPDF
4CPS-085 Assessment of the direct-acting antivirals used to treat the hepatitis c virus genotype 4 infection in a tertiary hospital
  1. JC del Río Valencia,
  2. L Villalobos Torres,
  3. R Asensi Diez,
  4. I Muñoz Castillo
  1. Regional University Hospital of Malaga, Pharmacy Service, Malaga, Spain


Background Hepatitis C is a serious disease with high prevalence, being the leading cause of liver transplantation. The development of well-tolerated and highly-effective direct acting antivirals (DAAs) for hepatitis C virus (HCV) has dramatically changed the therapeutic landscape

Purpose Assessing of the effectiveness of sofosbuvir/ledipasvir (SOF/LDV), paritaprevir/ombitasvir/ritonavir±ribavirin (PTV/OBV/r±RBV) and sofosbuvir/simeprevir (SOF+SIM) used for the treatment of the hepatitis C virus genotype-4 infection.

Material and methods Retrospective and observational study during year 2015. Inclusion criteria: patients with HCV genotype-4 infection treated for 12 weeks either with SOF/LDV or SOF+SIM or PTV/OBV/r±RBV during study period. Exclusion criteria: patients with no data available. Outcomes collected: demographics: age and sex. Clinical data: basal viral load (VL), SVR at week 12 (SVR12), defined as HCV RNA titres lower than 15 IU/mL. METAVIR score: F0 to F4. Liver transplant; HIV co-infection; previous treatments for HCV. Data were collected from the medical records of patients.

Results Treatment SOF/LDV: 21 patients were included (75% males) with mean age of 52±6.60 years. METAVIR score: F4 (cirrhosis) (33.33%); F3 (33.33%); F2 (19.04%) and F1 (14.28%). 66.66% patients were HIV-coinfected and no patients was liver transplanted. Fifty per cent were pretreated with ribavirin/peginterferon and 28.57% had a basal VL >800,000 UI/ml. All patients (21/21=100%) achieved SVR12.

Treatment SOF+SIM: 23 patients (86.95% males) were included with mean age 51.88±4.33 years. METAVIR score: F4 (cirrhosis) (47.82%); F3 (39.14%); F2 (13.04%). HIV-coinfected patients 43.47%, pretreated with ribavirin/peginterferon 52.17% and 52.17% had basal VL>800,000 UI/ml. 86.95% (20/23) achieved SVR12, one naive-non-cirrhotic patient and two pre-treated-cirrhotic patients did not get SVR12.

Treatment PTV/OBV/r±RBV: 26 patients (88.46% males) were included with mean age 51.60±4.34 years. METAVIR score: F4 (cirrhosis) (46.15%); F3 (38.46%); F2 (15.38%). HIV-coinfected patients 38.46%, pre-treated with ribavirin/peginterferon 19.23% and 50% had basal VL>800,000 UI/ml. 96.15% (25/26) achieved SVR12.

Conclusion The SVR12 rates achieved in this study with the treatments SOF/LDV and PTV/OBV/r±RBV match the results obtained in published clinical trials ION-4 and PEARL-I, respectively. In the SOF+SIM group, 86.95% achieved SVR12, which is slightly lower than the value obtained in the PLUTO study. Indeed, these new drugs show a high rate of response, which has revolutionised the management of chronic hepatitis C.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.